Teva To Sell Its Stake In Teva-Takeda Venture In Japan

Teva Pharmaceutical Industries Ltd. has announced an agreement to transfer all shares of its joint venture, Teva Takeda Pharma Limited, and its subsidiary, Teva Takeda Yakuhin Ltd., to JKI, a company established by J-Will's managed fund. This decision follows Teva's recent statement about exploring new strategies in Japan, including selling its Teva-Takeda business. 

The move aligns with Teva's Pivot to Growth strategy, enabling the company to concentrate on its innovative medicines in Japan. Teva expects the sale to be finalised by April 1, 2025, pending standard closing conditions, including necessary regulatory approvals. All employees involved in the business venture in Japan will keep their jobs, as outlined in the agreement.

Mark Sabag, Executive Vice President, International Markets Commercial, said in a statement, “This is another step in our Pivot to Growth strategy to focus the business. Furthermore, we are confident that this agreement with JKI will ensure the continued delivery of high-quality, affordable medicines to patients in Japan.”